Long-term glucose tolerance in highly experienced HIV-infected patients receiving nucleoside analogue-sparing regimens.
Article Details
- CitationCopy to clipboard
Bigoloni A, Gianotti N, Spagnuolo V, Galli L, Nozza S, Cossarini F, Salpietro S, Carini E, Piatti P, Vinci C, Lazzarin A, Castagna A
Long-term glucose tolerance in highly experienced HIV-infected patients receiving nucleoside analogue-sparing regimens.
AIDS. 2012 Sep 10;26(14):1837-40. doi: 10.1097/QAD.0b013e32835705dd.
- PubMed ID
- 22739393 [ View in PubMed]
- Abstract
Thirty-nine HIV-1-infected patients treated for 156 weeks with a new nucleoside analogue-sparing regimen [raltegravir, etravirine and maraviroc (REM) or raltegravir, etravirine and darunavir/ritonavir (RED)] showed a uniform increase in fasting glucose levels and a uniform decrease in insulin secretory capacity. Diabetes mellitus occurred in one RED-treated and four REM-treated patients. A worsening glucose tolerance was observed in highly treatment-experienced HIV-infected patients receiving effective antiretroviral therapy after virological failure.
DrugBank Data that Cites this Article
- Pharmaco-metabolomics
Drug Drug Groups Metabolite Change Description Etravirine Approved Glucose increased Etravirine increases the level of Glucose in the blood Raltegravir Approved Glucose increased Raltegravir increases the level of Glucose in the blood Ritonavir Approved Investigational Glucose increased Ritonavir increases the level of Glucose in the blood